These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 11584521

  • 21. Is concern about cardiovascular events with the new coxib class of drugs justified?
    Schnitzer TJ.
    Medscape Womens Health; 2001 Oct; 6(5):8. PubMed ID: 11698930
    [No Abstract] [Full Text] [Related]

  • 22. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
    Ann Intern Med; 2003 May 20; 138(10):I39. PubMed ID: 12755582
    [No Abstract] [Full Text] [Related]

  • 23. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 20; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 24. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
    Vanchieri C.
    J Natl Cancer Inst; 2005 Apr 20; 97(8):552-3. PubMed ID: 15840872
    [No Abstract] [Full Text] [Related]

  • 25. [New anti-inflammatory analgetics--are they needed?].
    Paakkari I.
    Duodecim; 1999 Apr 20; 115(20):2217-24. PubMed ID: 11973925
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Does the dose make the poison?
    Harris RE.
    Science; 2005 Apr 08; 308(5719):203. PubMed ID: 15821073
    [No Abstract] [Full Text] [Related]

  • 33. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM, Weber RJ, McKaveney TP, Ansani NT, Towers AL.
    Ann Pharmacother; 2003 Sep 08; 37(9):1203-13. PubMed ID: 12921500
    [Abstract] [Full Text] [Related]

  • 34. COX-2 inhibitors--lessons in drug safety.
    Psaty BM, Furberg CD.
    N Engl J Med; 2005 Mar 17; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract] [Full Text] [Related]

  • 35. [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
    Patrignani P.
    Acta Otorhinolaryngol Ital; 2003 Aug 17; 23(4 Suppl 74):13-8, 37-40. PubMed ID: 15058604
    [No Abstract] [Full Text] [Related]

  • 36. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
    MMW Fortschr Med; 2003 May 01; 145(18):54. PubMed ID: 12808824
    [No Abstract] [Full Text] [Related]

  • 37. [Cardiovascular ffects of COX-2 selective anti-inflammatory agents].
    Halinen MO.
    Duodecim; 2001 May 01; 117(24):2570-1. PubMed ID: 12183817
    [No Abstract] [Full Text] [Related]

  • 38. An update on specific COX-2 inhibitors: the COXIBs.
    Gupta S, Crofford LJ.
    Bull Rheum Dis; 2001 May 01; 50(1):1-4. PubMed ID: 12092091
    [No Abstract] [Full Text] [Related]

  • 39. Biomedicine. Back to an aspirin a day?
    Vane JR.
    Science; 2002 Apr 19; 296(5567):474-5. PubMed ID: 11964462
    [No Abstract] [Full Text] [Related]

  • 40. MI risk prompts rofecoxib withdrawal.
    Thompson CA.
    Am J Health Syst Pharm; 2004 Nov 01; 61(21):2234-6, 2238. PubMed ID: 15552625
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.